Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06810167
PHASE3

Assessing Tenapanor as a Treatment of CF-related Constipation.

Sponsor: Massachusetts General Hospital

View on ClinicalTrials.gov

Summary

Tenapanor is the newest FDA-approved drug for IBS with constipation (IBS-C). This study seeks to understand tenapanor as a treatment for cystic fibrosis-related constipation (CFrC) in CF patients. Participants will ingest one 50 mg tablet of tenapanor, twice daily, for a 4-week treatment period. They will also complete three questionnaires, the PAC-SYM, PAC-QoL, and IBS-SSS, and daily diaries to characterize GI symptom burden and spontaneous bowel movement (SBM) frequency.

Official title: An Open-label, Single Center Study Assessing Tenapanor as a Non-CFTR-mediated Treatment of CF-related Constipation in People With CF.

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

25

Start Date

2025-06-01

Completion Date

2027-06-30

Last Updated

2026-03-18

Healthy Volunteers

No

Interventions

DRUG

Tenapanor

CF patients with CFrC will ingest one 50 mg tablet of tenapanor twice daily for 4 weeks.

Locations (1)

Massachusetts General Hospital

Boston, Massachusetts, United States